Depressive symptoms and actigraphy-measured circadian disruption predict head and neck cancer survival

2018 ◽  
Vol 27 (10) ◽  
pp. 2500-2507 ◽  
Author(s):  
Elizabeth Cash ◽  
C. Riley Duck ◽  
Courtney Brinkman ◽  
Whitney Rebholz ◽  
Christy Albert ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Depressive Symptoms ◽  
Head And Neck ◽  
Neck Cancer ◽  
Cancer Survival ◽  
Circadian Disruption

scholarly journals Depressive symptoms predict head and neck cancer survival: Examining plausible behavioral and biological pathways

Cancer ◽  
2018 ◽  
Vol 124 (5) ◽  
pp. 1053-1060 ◽  
Author(s):  
Lauren A. Zimmaro ◽  
Sandra E. Sephton ◽  
Chelsea J. Siwik ◽  
Kala M. Phillips ◽  
Whitney N. Rebholz ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Depressive Symptoms ◽  
Head And Neck ◽  
Neck Cancer ◽  
Cancer Survival ◽  
Biological Pathways

scholarly journals Weight loss after head and neck cancer: A dynamic relationship with depressive symptoms

Head & Neck ◽  
2016 ◽  
Vol 39 (2) ◽  
pp. 370-379 ◽  
Author(s):  
Julia R. Van Liew ◽  
Rebecca L. Brock ◽  
Alan J. Christensen ◽  
Lucy Hynds Karnell ◽  
Nitin A. Pagedar ◽  
...  
Keyword(s):  
Weight Loss ◽  
Head And Neck Cancer ◽  
Depressive Symptoms ◽  
Head And Neck ◽  
Neck Cancer ◽  
Dynamic Relationship

Five-year Head and Neck Cancer Survival. The South West Audit of Head and Neck Cancer (SWAHN)

2010 ◽  
Vol 22 (10) ◽  
pp. 897
Author(s):  
S. Thomas ◽  
T. Mellor ◽  
D. Bailey ◽  
C. Drugan ◽  
A. Ness ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Cancer Survival ◽  
The South ◽  
South West

Health-related quality of life in head and neck cancer survivors: Impact of pretreatment depressive symptoms.

2010 ◽  
Vol 29 (1) ◽  
pp. 65-71 ◽  
Author(s):  
M. Bryant Howren ◽  
Alan J. Christensen ◽  
Lucy Hynds Karnell ◽  
Gerry F. Funk
Keyword(s):  
Quality Of Life ◽  
Head And Neck Cancer ◽  
Depressive Symptoms ◽  
Cancer Survivors ◽  
Head And Neck ◽  
Neck Cancer ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

scholarly journals Combined P16 and human papillomavirus testing predicts head and neck cancer survival

2014 ◽  
Vol 135 (10) ◽  
pp. 2404-2412 ◽  
Author(s):  
Christian R. Salazar ◽  
Nicole Anayannis ◽  
Richard V. Smith ◽  
Yanhua Wang ◽  
Missak Haigentz ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Human Papillomavirus ◽  
Head And Neck ◽  
Neck Cancer ◽  
Cancer Survival ◽  
Human Papillomavirus Testing

Sociodemographic correlates of head and neck cancer survival among patients with metastatic disease

Head & Neck ◽  
2020 ◽  
Vol 42 (9) ◽  
pp. 2505-2515 ◽  
Author(s):  
Jaibir S. Pannu ◽  
Matthew C. Simpson ◽  
Connor L. Donovan ◽  
Eric Adjei Boakye ◽  
Katherine Mass ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Metastatic Disease ◽  
Neck Cancer ◽  
Cancer Survival ◽  
Sociodemographic Correlates

The Association between Metformin and Survival of Head and Neck Cancer: A Systematic Review and Meta-Analysis of 7 Retrospective Cohort Studies

2020 ◽  
Vol 26 (26) ◽  
pp. 3161-3170 ◽  
Author(s):  
Yongbo Wang ◽  
Tao Fu ◽  
Yu Liu ◽  
Guifang Yang ◽  
Chuanhua Yu ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Cohort Studies ◽  
Head And Neck ◽  
Neck Cancer ◽  
Retrospective Cohort ◽  
Cancer Survival ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Cochrane Library ◽  
Retrospective Cohort Studies

Background: Metformin has been associated with improved survival outcomes in various malignancies. However, observational studies in head and neck cancer are inconsistent. Objective: The study aimed to summarize and quantify the relationship between metformin use and the survival of head and neck cancer. Methods: A meta-analysis based on cohort studies was systematically conducted (published up to Jan 18, 2020), identified from PubMed, Embase, Web of Science, Cochrane Library, Google Scholar, and Scopus databases. Summary hazard ratios (HR) and 95% confidence intervals (CI) were calculated using a random-effects model. Results: Seven retrospective cohort studies including 3,285 head and neck cancer patients were included. The association between the use of metformin and cancer survival was not statistically significant: summarized HR of 0.89 (95% CI 0.66-1.18, P=0.413, I2=64.0%) for overall survival, summarized HR of 0.65 (95% CI 0.31-1.35, P=0.246, I2=60.3%) for disease-free survival, and summarized HR of 0.69 (95% CI 0.40-1.20, P=0.191, I2=73.1%) for disease-specific survival. Conclusion: In this meta-analysis of 7 retrospective cohort studies, there was not a statistically significant association between the use of metformin and better survival for head and neck cancer. However, the analysis may have been underpowered. More studies of prospective designs with larger sample sizes are needed to investigate the effect of metformin on the survival of head and neck cancer.

Sign in / Sign up

Export Citation Format

Share Document